Zidebactam
- Generic Name
- Zidebactam
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C13H21N5O7S
- CAS Number
- 1436861-97-0
- Unique Ingredient Identifier
- YPM97423DB
- Background
Zidebactam is under investigation in clinical trial NCT02674347 (MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults).
- Associated Conditions
- -
- Associated Therapies
- -
What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing
CLSI Subcommittee on Antimicrobial Susceptibility Testing introduced changes including breakpoint revisions and new breakpoints in 2024. Phenotypic criteria for carbapenemase testing among Enterobacterales were updated to improve clinical care. Investigational breakpoints for cefepime and zidebactam were proposed for carbapenem-resistant pathogens. Breakpoints for Acinetobacter baumannii were also updated, focusing on ampicillin/sulbactam and minocycline.
Related Clinical Trials:
FDA grants fast track designation to Wockhardt's novel antibiotic WCK 6777
FDA grants Fast Track designation to Wockhardt's once-a-day antibiotic WCK 6777 for cUTI and cIAI. WCK 6777, active against meropenem-resistant Gram negative pathogens, completed a Phase I study with a promising safety profile.
WCK 6777 passes trials; FDA grants fast track status to antibiotic for complicated UTIs
Wockhardt's WCK 6777, a once-a-day β-lactam enhancer antibiotic, successfully completed Phase I study by NIH's DMID, showing promising safety profile. FDA granted Fast Track designation for cUTI and cIAI treatment. WCK 6777 is designed for outpatient-parenteral antimicrobial therapy, active against meropenem-resistant Gram negative pathogens, potentially reducing hospital admissions and costs.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath